inflammatory diseases

Mestag Signs License and Research Deal with Merck & Co.

Mestag Therapeutics, a Cambridge, UK-headquartered biotech company working on new insights into fibroblast-immune interactions, has signed a license and collaboration agreement with US drugmaker Merck & Co., known as MSD outside of North America, to identify novel targets for the development of therapies against inflammatory diseases.

Resilience and Mubadala in Biopharma Venture

US biopharma manufacturing and technology company National Resilience has entered into an agreement with Abu Dhabi investor Mubadala Investment Company to build a manufacturing plant in the United Arab Emirate’s biggest city. This will be the first GMP biopharma facility in the UAE.

Gilead Buys Oxford Spin-out MiroBio

Gilead Sciences has agreed to acquire MiroBio, a privately held UK biotech focused on treating inflammatory diseases, for about $405 million in cash.

Boehringer Wins Europe’s First Biosimilar Approval